Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) just unveiled an announcement.
Pharmaron Beijing Co., Ltd. has announced an updated cash dividend for the year ending December 31, 2024, with a declared dividend of RMB 2 per 10 shares. The announcement includes key dates such as the ex-dividend date on July 4, 2025, and the payment date on August 6, 2025. The company also outlined the withholding tax rates applicable to different categories of shareholders, which may impact non-resident and domestic investors differently. This dividend announcement reflects the company’s financial strategy and could influence investor sentiment and market positioning.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. operates in the pharmaceutical industry, providing a range of services including drug research and development, manufacturing, and testing. The company focuses on offering comprehensive solutions to pharmaceutical companies worldwide, enhancing their drug development processes.
Average Trading Volume: 8,222,394
Technical Sentiment Signal: Buy
Current Market Cap: HK$40.73B
For a thorough assessment of 3759 stock, go to TipRanks’ Stock Analysis page.